PMID- 24713399
OWN - NLM
STAT- MEDLINE
DCOM- 20150413
LR  - 20140812
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
VI  - 47
IP  - 12
DP  - 2014 Aug
TI  - Brain-derived neurotrophic factor blood levels are decreased in schizophrenia 
      patients and associate with rs6265 genotypes.
PG  - 1052-5
LID - S0009-9120(14)00163-5 [pii]
LID - 10.1016/j.clinbiochem.2014.03.021 [doi]
AB  - OBJECTIVES: A growing number of studies implicate brain-derived neurotrophic 
      factor (BDNF), an important promoter of synaptic transmission and neural 
      plasticity, in the pathogenesis of schizophrenia. However, the existing data are 
      controversial, that may reflect population differences between studied groups. 
      DESIGN AND METHODS: In the present study we performed a comparative analysis of 
      BDNF plasma levels and its relation with rs6265 (G196A; Val66Met) polymorphism of 
      BDNF gene (BDNF) in schizophrenia-affected and healthy subjects (controls) of the 
      Armenian population. To check the influence of antipsychotics on BDNF plasma 
      levels both medicated and non-medicated patients were involved in this study. 
      Patients with paranoid form of schizophrenia chronically treated with typical 
      antipsychotics (n=103), age- and sex-matched controls (n=105), and 25 
      antipsychotic-naive first-episode schizophrenia patients were involved. The 
      levels of BDNF in the blood plasma were measured with a solid-phase enzyme-linked 
      immunosorbent assay. RESULTS: Decreased plasma levels of BDNF in both medicated 
      and non-medicated schizophrenia patients compared to controls were observed. No 
      significant difference in BDNF levels between medicated and non-medicated 
      patients was detected. It was also detected that, compared to individuals 
      homozygous for the standard allele (G/G) of rs6265, carriers of the rs6265 minor 
      allele (A/G+A/A), which is significantly more frequent in schizophrenia patients 
      than in controls, had decreased BDNF levels. CONCLUSIONS: The data obtained 
      suggested that the pathogenesis of schizophrenia is characterized by genetically 
      predetermined decreased blood levels of BDNF. These results indicated that 
      genetically determined alterations of neuroimmune modulators may be among the 
      risk factors of schizophrenia and contribute to disease-specific pathologic 
      changes in functional activity of both the neuronal synaptic plasticity and the 
      immune system.
CI  - Copyright (c) 2014 The Canadian Society of Clinical Chemists. Published by Elsevier 
      Inc. All rights reserved.
FAU - Zakharyan, Roksana
AU  - Zakharyan R
AD  - Institute of Molecular Biology, National Academy of Sciences of the Republic of 
      Armenia (NAS RA), 7 Hasratyan St., 0014 Yerevan, Armenia. Electronic address: 
      r_zakharyan@mb.sci.am.
FAU - Boyajyan, Anna
AU  - Boyajyan A
AD  - Institute of Molecular Biology, National Academy of Sciences of the Republic of 
      Armenia (NAS RA), 7 Hasratyan St., 0014 Yerevan, Armenia. Electronic address: 
      aboyajyan@sci.am.
LA  - eng
PT  - Journal Article
DEP - 20140405
PL  - United States
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
RN  - 0 (Brain-Derived Neurotrophic Factor)
SB  - IM
MH  - Adult
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Schizophrenia/*blood/genetics
OTO - NOTNLM
OT  - Brain-derived neurotrophic factor
OT  - Plasma levels
OT  - Schizophrenia
OT  - rs6265 Polymorphism
EDAT- 2014/04/10 06:00
MHDA- 2015/04/14 06:00
CRDT- 2014/04/10 06:00
PHST- 2013/12/22 00:00 [received]
PHST- 2014/03/22 00:00 [revised]
PHST- 2014/03/28 00:00 [accepted]
PHST- 2014/04/10 06:00 [entrez]
PHST- 2014/04/10 06:00 [pubmed]
PHST- 2015/04/14 06:00 [medline]
AID - S0009-9120(14)00163-5 [pii]
AID - 10.1016/j.clinbiochem.2014.03.021 [doi]
PST - ppublish
SO  - Clin Biochem. 2014 Aug;47(12):1052-5. doi: 10.1016/j.clinbiochem.2014.03.021. 
      Epub 2014 Apr 5.